表紙
市場調查報告書

焦點市場分析:偏頭痛

Market Spotlight: Migraine

出版商 Datamonitor Healthcare 商品編碼 573555
出版日期 內容資訊 英文 67 Pages
商品交期: 最快1-2個工作天內
價格
焦點市場分析:偏頭痛 Market Spotlight: Migraine
出版日期: 2020年01月14日內容資訊: 英文 67 Pages
簡介

據估計,2017年全球20歲及以上人口的偏頭痛患者人數為5.796億,預計到2026年將增加至6.492億。就各地區別來看,拉丁美洲加勒比海地區的盛行率16.4%最高,而北美的患病率最低,為9.7%。大多數批准的藥物都針對5-羥色胺5-HT1受體或GABA受體,主要的給藥途徑是口服途徑,以及靜脈內,鼻內,肌內,皮內,關節內,膀胱內,直腸,有少量舌下,口服透粘膜和皮下製劑。大多數正在開發的藥物都處於第三階段,目標廣泛。美國是按地區劃分的臨床試驗世界領導者,歐盟則是德國,亞洲日本居首。

本報告提供全球偏頭痛治療藥的市場調查,彙整疾病的背景·概要,患病人數的10年預測,開發平台藥物及已上市藥概要,臨床試驗狀況,授權·資產收購等的主要交易趨勢,專利資訊,主要藥物的收益預測等資料。

概要

要點

疾病的背景

  • 徵兆的沒有的偏頭痛
  • 徵兆伴隨的偏頭痛

治療

  • 止痛藥
  • NSAIDs (非類固醇系消炎止痛藥)
  • 血清素劑
  • CGRP抑制劑
  • 預防的藥物

流行病學

已上市藥物

開發平台藥物

近幾年的發展·分析師的見解

今後的發展

法律規章上的發展

授權·資產取得契約

成功概率

本源專利

商機

臨床試驗環境

  • 贊助商:各狀態
  • 贊助商:不同階段
  • 近幾年的發展

文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0178453

This Market Spotlight report covers the migraine market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2017, there were 579.6 million prevalent cases of migraine in adults aged 20 years and older worldwide, and forecasts that number to increase to 649.2 million prevalent cases by 2026. Latin America and the Caribbean is estimated to have the highest disease prevalence (16.4%), while Northern America has the lowest prevalence (9.7%).

The majority of approved drugs in the migraine space target the serotonin 5-HT1 receptor or GABA receptors. These are commonly administered via the oral route, with a smaller number of products being available in intravenous, intranasal, intramuscular, intradermal, intraarticular, intravesical, rectal, sublingual, oral transmucosal, and subcutaneous formulations.

The largest proportion of industry-sponsored drugs in active clinical development for migraine are in Phase III. Drugs in development for migraine focus on a wide variety of targets. Approximately half of the drugs in development for migraine are administered via the oral route, with the remainder being intranasal, inhaled, subcutaneous, intravenous, topical, transdermal, sublingual, oral transmucosal, and intramuscular formulations.

High-impact upcoming events for drugs in the migraine space comprise topline Phase II, Phase II/III, Phase III, and Phase IIIb trial results, an expected supplemental CHMP opinion, and FDA decisions on NDAs and a BLA.

The overall likelihood of approval of a Phase I migraine and other headaches asset is 15.4%, and the average probability a drug advances from Phase III is 93.8%. Drugs, on average, take 7.6 years from Phase I to approval, compared to 9.8 years in the overall neurology space.

There have been 28 licensing and asset acquisition deals involving migraine drugs during 2015-20. The largest deal was the $573.5m exclusive agreement between Bristol-Myers Squibb and Biohaven in 2016 to develop and commercialize rimegepant and BHV-3500, as well as for rights to other CGRP-related intellectual property.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for migraine have been in the early and mid-phases of development, with 55% of trials in Phase I-II, and 45% in Phase III-IV.

The US has a substantial lead in the number of migraine clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.

Clinical trial activity in the migraine space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for migraine, with 95 trials.

GlaxoSmithKline leads the industry sponsors with by far the highest overall number of clinical trials for migraine, followed by Eli Lilly and Merck & Co.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Migraine without aura
  • Migraine with aura

TREATMENT

  • Analgesics
  • NSAIDs
  • Serotonergic drugs
  • CGRP inhibitors
  • Prophylactic agents for migraine

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • AXS-07 for Migraine (December 30, 2019)
  • Vazegepant for Migraine (December 17, 2019)
  • Emgality for Migraine (August 5, 2019)
  • Multiple Drugs for Migraine (June 25, 2019)
  • Emgality for Migraine (May 8, 2019)
  • Eptinezumab for Migraine (May 8, 2019)
  • Ubrelvy for Migraine (May 8, 2019)
  • Rimegepant for Migraine (May 7, 2019)
  • Atogepant for Migraine (May 6, 2019)
  • Emgality for Migraine (May 6, 2019)
  • Eptinezumab for Migraine (May 6, 2019)
  • Ajovy for Migraine (April 23, 2019)
  • Emgality for Migraine (April 1, 2019)
  • SpringTMS for Migraine (February 27, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Allergan's Oral CGRP Inhibitor Ubrelvy Approved For Migraine Attacks
  • Lilly Expands Migraine Franchise With Reyvow Approval
  • IntelGenx Takes A Fourth Try At Rizaport Approval
  • Global Device Approvals Snapshot: 9-15 July 2019
  • CGRP Inhibitor Review Pipeline Grows With Biohaven's Rimegepant Submission
  • Theranica's Smartphone-Controlled Migraine Device Earns FDA De Novo
  • CMC Issues Derail Rizaport. Again.
  • Biohaven Pays $105m For Turbo Boost In Migraine Drug Review Race
  • Allergan Aims To Broaden CGRP Class With First Oral Candidate For Acute Migraine
  • Alder Bids To Join Anti-CGRP Fray With Promise Of Rapid Onset, Infusion Delivery
  • Teva's Ajovy Gets EU Thumbs Up From CHMP
  • Promius' Tosymra Is First Approval Using Neurelis' Intravail Technology

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Currax Gains NA License To Optinose's Onzetra Xsail Migraine Treatment
  • Deals Shaping The Medical Industry, October 2019
  • Lundbeck CEO: Alder Buy Will Boost Pipeline
  • Upsher-Smith Completes Acquisition Of Dr Reddy's Two Migraine Treatments
  • Kurve, Seurat Collaborate On Nasal Spray For Migraines
  • Upsher-Smith Snaps Up Migraine Assets As Dr Reddy's Hones Focus
  • No More Deal? Novartis, Amgen Trade Lawsuits Over Aimovig Agreements

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of migraine, 2017-26
  • Figure 2: Overview of pipeline drugs for migraine in the US
  • Figure 3: Pipeline drugs for migraine, by company
  • Figure 4: Pipeline drugs for migraine, by drug type
  • Figure 5: Pipeline drugs for migraine, by classification
  • Figure 6: AXS-07 for Migraine (December 30, 2019): Phase III - MOMENTUM (Acute)
  • Figure 7: Vazegepant for Migraine (December 17, 2019): Phase II/III - 201
  • Figure 8: Emgality for Migraine (August 5, 2019): Phase III - CONQUER
  • Figure 9: Eptinezumab for Migraine (May 8, 2019): Phase III - PROMISE 1 (High Frequency; IV)
  • Figure 10: Ubrelvy for Migraine (May 8, 2019): Phase III - ACHIEVE II (UBR-MD-02)
  • Figure 11: Rimegepant for Migraine (May 7, 2019): Phase III - BHV3000-303 (ODT Formulation)
  • Figure 12: Emgality for Migraine (May 6, 2019): Phase III - EVOLVE-1 (Episodic Migraine), Phase III - EVOLVE-2 (Episodic Migraine)
  • Figure 13: Eptinezumab for Migraine (May 6, 2019): Phase III - PROMISE 2 (Chronic; IV)
  • Figure 14: Key upcoming events in migraine
  • Figure 15: Probability of success in the migraine pipeline
  • Figure 16: Licensing and asset acquisition deals in migraine, 2015-20
  • Figure 17: Parent patents in migraine, 2019-28
  • Figure 18: Parent patents in migraine, 2030-37
  • Figure 19: Clinical trials in migraine
  • Figure 20: Top 10 drugs for clinical trials in migraine
  • Figure 21: Top 10 companies for clinical trials in migraine
  • Figure 22: Trial locations in migraine
  • Figure 23: Migraine trials status
  • Figure 24: Migraine trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of migraine, 2017-26
  • Table 2: Prevalence proportions, 2017-26
  • Table 3: Marketed drugs for migraine
  • Table 4: Pipeline drugs for migraine in the US
  • Table 5: AXS-07 for Migraine (December 30, 2019)
  • Table 6: Vazegepant for Migraine (December 17, 2019)
  • Table 7: Emgality for Migraine (August 5, 2019)
  • Table 8: Multiple Drugs for Migraine (June 25, 2019)
  • Table 9: Emgality for Migraine (May 8, 2019)
  • Table 10: Eptinezumab for Migraine (May 8, 2019)
  • Table 11: Ubrelvy for Migraine (May 8, 2019)
  • Table 12: Rimegepant for Migraine (May 7, 2019)
  • Table 13: Atogepant for Migraine (May 6, 2019)
  • Table 14: Emgality for Migraine (May 6, 2019)
  • Table 15: Eptinezumab for Migraine (May 6, 2019)
  • Table 16: Ajovy for Migraine (April 23, 2019)
  • Table 17: Emgality for Migraine (April 1, 2019)
  • Table 18: SpringTMS for Migraine (February 27, 2019)
  • Table 19: Historical global sales, by drug ($m), 2014-18
  • Table 20: Forecasted global sales, by drug ($m), 2020-24